The FTC has released a second report on PBMs, focusing on pharmacy benefit managers’ influence over specialty generic drugs, including significant price markups by PBMs for cancer, HIV, and other critical drugs.

A bipartisan group of lawmakers has introduced a bill requiring pharmacy benefit managers (PBMs) and health insurers to divest their ownership of pharmacies. This move addresses criticism that PBMs' vertical integration creates monopolies in American healthcare, driving up prescription costs.

A report discusses how the business practices of PBMs are leading to the closure of independent pharmacies, resulting in reduced access to medications for many communities. The article highlights the need for regulatory scrutiny of PBM operations.

There is increasing advocacy for the FTC to examine PBMs' co-manufacturing agreements and their impact on drug pricing. Critics argue that these relationships may be contributing to anticompetitive practices and higher consumer costs.

An investigative article examines how PBMs' confidential negotiations and rebate practices may have contributed to rising drug prices and the opioid crisis. The report suggests that PBMs' influence on drug formularies and pricing has had significant public health implications.